Treatment persistence and changes in fracture risk, back pain, and quality of life amongst patients treated with teriparatide in routine clinical care in France: results from the European Forsteo Observational Study

Effective osteoporosis treatment with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis: the European Forsteo Observational Study

Effectiveness of Teriparatide in women over 75 years of age with severe osteoporosis: 36-month results from the European Forsteo Observational Study (EFOS)

Effectiveness of teriparatide in postmenopausal women with osteoporosis and glucocorticoid use: 3-year results from the EFOS study

Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study

Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS)

Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS)

Characterization of patients in the European Forsteo Observational Study (EFOS): postmenopausal women entering teriparatide treatment in a community setting

Vitamin D supplementation in patients with chronic kidney disease

Septic arthritis of the hip with Propionibacterium avidum bacteremia after intraarticular treatment for hip osteoarthritis

Off-label prescribing in a French hospital

Postmenopausal osteoporosis and atheroma

Management of glucocorticoid-induced osteoporosis: lessons for clinical practice

Glucocorticoid-induced osteoporosis: when and who should we treat?

Cardiac and arterial calcifications and all-cause mortality in the elderly: the PROTEGER Study

Serum uric acid and cardiovascular risk: state of the art and perspectives

Major immunoglobulin capping deficiency in the peripheral blood B cells of patients with Sjögren's syndrome